Artesunate/mefloquine Artesunate/mefloquine Artesunate/mefloquine is a medication used to treat malaria. It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria. It is taken by mouth. Side effects are similar to the medications being used separately. Use is recommended as it decreases the possibility of either medications being used alone. Dose forms appropriate for children are also available. Artesunate/mefloquine came into commercial use in 2008. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is approved for medical use
Drugs for Neglected Diseases Initiative in 32 African countries, in India, Ecuador and in Colombia, and included in the WHO Model List of Essential Medicines. More than 437 million treatments had been distributed. A technology transfer agreement has been signed with industrial partner Zenufa in Tanzania in order to provide an additional source of ASAQ. ASAQ was handed over to the MMV Access and Product Management Team in May 2015. The second antimalarial treatment developed by DND"i" is a fixed-dose combination of artesunate and mefloquine launched in 2008. It was developed by an international collaboration within the FACT Project Consortium. It has a simple and